Amgen Inc (NASDAQ:AMGN) – Amgen And AstraZeneca Announce Positive Results From Phase 3 Study Of Brodalumab (AMG 827) In Patients With Moderate-to-Severe Plaque Psoriasis

[PR Newswire] – THOUSAND OAKS, Calif. and LONDON, May 9, 2014 /PRNewswire/ — Amgen (AMGN) and AstraZeneca today announced that the Phase 3 AMAGINE-1TM study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis . . . → Read More: Amgen Inc (NASDAQ:AMGN) – Amgen And AstraZeneca Announce Positive Results From Phase 3 Study Of Brodalumab (AMG 827) In Patients With Moderate-to-Severe Plaque Psoriasis Similar Articles: Stock Update: Amgen Inc (NASDAQ:AMGN) – Amgen Announces Webcast of 2014 First Quarter Financial Results Amgen Inc (NASDAQ:AMGN) – Amgen To Webcast Investor Meeting At Upcoming American College of Cardiology’s 63rd Annual Scientific Session Merck & Co. Inc. (NYSE:MRK) – 8:31 am Merck initiates rolling submission of U.S. Biologics License Application for MK-3475, an investigational Anti-PD-1 Immunotherapy, in patients with advanced melanoma; expects to complete application in 1H14